CUTANEOUS VASCULAR EFFECTS OF PULSED DYE LASER IN COMBINATION WITH BEVACIZUMAB

$3,016P41FY2009RRNIH

University Of California-Irvine, Irvine CA

Investigators

Linked publications & trials

Paper 35023333 Paper 32610090 Paper 31958703 Paper 31542152 Paper 30317006 Paper 30117930 Paper 29507905 Paper 29226023 Paper 28943709 Paper 28727869 Paper 28706755 Paper 28007783 Paper 27966347 Paper 27797529 Paper 27480804 Paper 27086689 Paper 27013846 Paper 26719944 Paper 26265042 Paper 25993434 Paper 25779479 Paper 25309621 Paper 24932051 Paper 24748724 Paper 24686168 Paper 24678143 Paper 24648368 Paper 24615671 Paper 24610460 Paper 24489722 Paper 24489440 Paper 24487897 Paper 24443649 Paper 24439339 Paper 24439047 Paper 24433713 Paper 24409388 Paper 24365846 Paper 24324008 Paper 24298424 Paper 24296952 Paper 24284732 Paper 24209868 Paper 24202858 Paper 24176195 Paper 24156076 Paper 24156075 Paper 24156056 Paper 24155140 Paper 24145701 Paper 24104815 Paper 24086090 Paper 24066941 Paper 24064949 Paper 24058206 Paper 24037939 Paper 24005154 Paper 23996592 Paper 23945533 Paper 23938961 Paper 23915805 Paper 23913068 Paper 23848807 Paper 23795150 Paper 23773096 Paper 23681033 Paper 23675654 Paper 23619900 Paper 23553270 Paper 23520655 Paper 23440713 Paper 23433249 Paper 23392340 Paper 23372668 Paper 23322707 Paper 23307439 Paper 23278596 Paper 23253891 Paper 23245525 Paper 23239900 Paper 23235925 Paper 23226872 Paper 23224004 Paper 23223999 Paper 23221044 Paper 23214170 Paper 23213008 Paper 23207399 Paper 23180029 Paper 23123971 Paper 23085984 Paper 23082305 Paper 23027244 Paper 23018764 Paper 22971344 Paper 22912719 Paper 22911574 Paper 22894472 Paper 22894465 Paper 22894457

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Pulsed dye laser treatment of vascular lesions is effective for some patients but multiple treatments are required and most patients do not achieve complete clearance. We have defined several reasons for limited efficacy. One important issue is vessel recurrence after treatment. Bevacizumab is an FDA approved anti-angiogenic agent which might diminish vessel recurrence post-treatment. Current investigations will use a mouse dorsal skinfold model and will be performed with Dr. Bernard Choi.

View original record on NIH RePORTER →